Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants.
In respiratory syncytial virus (RSV) disease the balance between the innate and adaptive immune responses determines the expression of the pathological phenotype favoring the development of acute bronchiolitis, and in certain children the development of recurrent wheezing. While humoral antibody plays a major role in protection against disease, T-cell immunity targeted to viral proteins appears to terminate viral infection. At the moment, treatment modalities for acute RSV infection do not effectively modify the course of the disease, and RSV vaccine development has shown conflicting results. To date, however, passive immunoprophylaxis with monoclonal antibodies is the only strategy that has demonstrated consistent efficacy in reducing RSV hospitalizations in high-risk children. The potential benefit of new strategies for prevention and treatment of RSV infections should be evaluated with respect to both the acute infection as well as the chronic respiratory manifestations induced by RSV.
Mejías
Asunción
A
Division of Pediatric Infectious Diseases, The University of Texas, Southwestern Medical Center and Children's Medical Center, Dallas, Texas, USA.
Ramilo
Octavio
O
Virology. 2004 Jan 20;318(2):608-12
14972528
Pediatrics. 2003 Dec;112(6 Pt 1):1442-6
14654627
J Infect Dis. 1997 Nov;176(5):1215-24
9359721
J Infect Dis. 1998 Dec;178(6):1555-61
9815203
Pediatrics. 1998 Sep;102(3):531-7
9724660
Pediatr Infect Dis J. 1999 Oct;18(10):866-9
10530581
J Pediatr. 2003 Oct;143(4):532-40
14571236
N Engl J Med. 1993 Nov 18;329(21):1524-30
8413475
Antimicrob Agents Chemother. 2004 May;48(5):1811-22
15105140
J Infect Dis. 2004 May 15;189(10):1856-65
15122522
Paediatr Respir Rev. 2004;5 Suppl A:S179-84
14980267
J Allergy Clin Immunol. 2004 Jan;113(1):127-33
14713917
J Infect Dis. 2004 Dec 1;190(11):1941-6
15529258
Pediatr Res. 2004 Dec;56(6):914-7
15470202
J Virol. 2004 Apr;78(8):4363-9
15047850
JAMA. 1999 Oct 20;282(15):1440-6
10535434
Treat Respir Med. 2006;5(6):483-94
17154675
Pediatr Pulmonol. 2008 Feb;43(2):169-74
18085710
J Pediatr. 1976 Jul;89(1):11-5
180274
Pediatr Cardiol. 2008 Mar;29(2):382-7
17926087
J Pediatr. 1998 Oct;133(4):492-9
9787686
J Virol. 2004 Aug;78(16):8753-60
15280483
J Infect Dis. 2002 May 1;185(9):1222-8
12001038
J Pediatr. 2007 Jul;151(1):34-42, 42.e1
17586188
Am J Respir Crit Care Med. 2005 Jan 15;171(2):137-41
15516534
J Virol. 1999 Jul;73(7):5852-64
10364337
Pediatr Infect Dis J. 1998 Sep;17(9):787-91
9779762
N Engl J Med. 1984 Dec 27;311(26):1653-8
6504106
Pediatrics. 1997 Jan;99(1):93-9
8989345
Pediatr Pulmonol. 2003 Jun;35(6):484-9
12746948
Am J Dis Child. 1986 Jun;140(6):543-6
3706232
J Pediatr. 2007 Sep;151(3):266-70, 270.e1
17719935
J Virol. 1989 Jul;63(7):2941-50
2470922
Ann Intern Med. 1978 Feb;88(2):203-5
415653
Lancet. 1999 Aug 14;354(9178):541-5
10470697
Antimicrob Agents Chemother. 2005 Nov;49(11):4700-7
16251314
J Infect Dis. 2004 Sep 1;190(5):975-8
15295704